Stimulation of angiogenesis to improve the viability of prefabricated flaps.
The cutaneous area in a prefabricated myocutaneous flap surviving after elevation is dependent on the rate and amount of vascular ingrowth that occurs from the underlying muscle. Two modalities, basic fibroblast growth factor and hyperbaric oxygen, were used separately and together in a prefabricated myocutaneous flap animal model to improve flap survival. The semimembranous muscle, based on the saphenous vessels of 40 female Wistar rats weighing between 250 and 325 grams, was tunneled under the ipsilateral abdominal skin and sutured in place. A 3 x 5-cm silicone sheet was placed beneath the muscle flap, and the ipsilateral epigastric vessels were ligated. Four groups of 10 animals each received one of the following treatment regimes: a 1-ml normal saline infusion into the saphenous arterial pedicle, a 1-ml infusion of basic fibroblast growth factor (1.0 microg/gm of muscle), a 1-ml normal saline infusion and 14 hyperbaric oxygen treatments, or a 1-ml basic fibroblast growth factor infusion and 14 hyperbaric oxygen treatments. After 1 week, the muscle, still based on the saphenous vessels, was elevated with a 3 x 5-cm abdominal skin paddle. The flap was sutured back in place, leaving the silicone sheet intact. The surviving area of each flap was measured 1 week later after it had demarcated into viable and necrotic regions. Laser Doppler skin perfusion measurements were taken before and after flap elevation and before animal euthanasia. Sixteen flaps, 4 in each group, were examined histologically for vascularity by means of hematoxylin and eosin staining. There was a statistically significant increase in flap survival area when either basic fibroblast growth factor or hyperbaric oxygen was used alone. Further improvement was noted with combination therapy. Histology confirmed improved vascularity in the basic fibroblast growth factor and hyperbaric oxygen-treated flaps. This study shows a significant and reliable increase in the area of prefabricated myocutaneous flap survival using either basic fibroblast growth factor or hyperbaric oxygen. There is a further complementary effect when these two modalities are combined, leading to near complete flap survival through improved vascularity.
Bayati
S
S
Southern Illinois University, School of Medicine, Institute for Plastic and Reconstructive Surgery, Springfield 62794-9230, USA.
Russell
R C
RC
Roth
A C
AC
D000005:Abdomen / Q000601:surgery; D000818:Animals; D001158:Arteries; D004396:Coloring Agents; D004195:Disease Models, Animal; D004801:Eosine Yellowish-(YS); D019074:Epigastric Arteries / Q000601:surgery; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use; D005456:Fluorescent Dyes; D006085:Graft Survival / Q000187:drug effects; D006416:Hematoxylin; D006931:Hyperbaric Oxygenation; D017078:Laser-Doppler Flowmetry; D018482:Muscle, Skeletal / Q000098:blood supply / Q000473:pathology / Q000637:transplantation; D009336:Necrosis; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D012501:Saphenous Vein; D012828:Silicones; D016038:Skin Transplantation / Q000473:pathology; D012965:Sodium Chloride; D013524:Surgical Flaps / Q000098:blood supply* / Q000473:pathology; D013526:Surgical Mesh
D004396:Coloring Agents; D005456:Fluorescent Dyes; D012828:Silicones; D016222:Fibroblast Growth Factor 2; D012965:Sodium Chloride; D004801:Eosine Yellowish-(YS); D006416:Hematoxylin